1. Home
  2. CADL vs DFP Comparison

CADL vs DFP Comparison

Compare CADL & DFP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

N/A

Current Price

$4.99

Market Cap

455.8M

Sector

Health Care

ML Signal

N/A

Logo Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.

DFP

Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.

N/A

Current Price

$18.25

Market Cap

386.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CADL
DFP
Founded
1999
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
455.8M
386.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
CADL
DFP
Price
$4.99
$18.25
Analyst Decision
Strong Buy
Analyst Count
10
0
Target Price
★ $17.67
N/A
AVG Volume (30 Days)
★ 1.4M
67.4K
Earning Date
11-12-2026
01-01-0001
Dividend Yield
N/A
★ 6.73%
EPS Growth
★ 58.62
N/A
EPS
N/A
★ N/A
Revenue
★ $125,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.35
$18.30
52 Week High
$14.00
$22.05

Technical Indicators

Market Signals
Indicator
CADL
DFP
Relative Strength Index (RSI) 25.65 34.49
Support Level $4.62 N/A
Resistance Level $5.51 $19.32
Average True Range (ATR) 0.70 0.26
MACD -0.33 -0.06
Stochastic Oscillator 1.62 10.66

Price Performance

Historical Comparison
CADL
DFP

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

About DFP Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.

Flaherty & Crumrine Dynamic Preferred and Income Fund Inc is a diversified, closed-end management investment company. Its investment objective is to seek total return, with an emphasis on high current income.

Share on Social Networks: